KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies.

Martin Desrosiers, Scott Nash, Andrew Lane, Stella E Lee, Eugenio De Corso, Changming Xia, Mark Corbett, Amr Radwan, Paul J Rowe, Yamo Deniz

Adv Ther 42(12) 5980-5993

PMID41014486
PMCIDPMC12680862
DOI10.1007/s12325-025-03378-2
发表日期2025-09-27
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。
摘要

摘要

INTRODUCTION: Nasal congestion/obstruction (NC) contributes to the high disease burden in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). Patient perception of NC may not accurately reflect nasal patency, while peak nasal inspiratory flow (PNIF) is an objective method with established thresholds for normal nasal airflow. This analysis evaluated the association between NC and PNIF and the impact of baseline PNIF on dupilumab efficacy in patients with severe CRSwNP. METHODS: This was a post hoc analysis of patients treated with placebo or dupilumab 300 mg every 2 weeks in the SINUS-24 (NCT02912468) and SINUS-52 (NCT02898454) phase III studies. Patients provided daily e-diary measures of PNIF (L/min) using PNIF meters, and NC by patient-reported evaluation of severity (scored 0-3). Other assessed outcomes were nasal polyp score (NPS), 22-item Sinonasal Outcome Test (SNOT-22), loss of smell (LoS), University of Pennsylvania Smell Identification Test (UPSIT), and Lund-Mackay computed tomography. Outcomes were assessed in two subgroups: baseline PNIF < 120 L/min and ≥ 120 L/min. RESULTS: Of 724 patients, 552 (76%) had PNIF < 120 L/min and 172 (24%) had PNIF ≥ 120 L/min at baseline. The PNIF < 120 L/min subgroup had higher mean scores for NPS and SNOT-22 and more smell impairment (LoS and UPSIT). PNIF weakly correlated with NC at baseline (Spearman coefficient - 0.348 [95% CI - 0.410, - 0.282], P < 0.0001). Correlations between change from baseline in PNIF and NC at week 24 were weak in the dupilumab group (- 0.390 [- 0.468, - 0.305], P < 0.0001) and moderate in the placebo group (- 0.497 [- 0.582, - 0.399], P < 0.0001). CONCLUSION: These results confirm PNIF as a valuable method for assessing nasal obstruction in patients with severe CRSwNP. The degree of nasal flow impairment at baseline does not impact dupilumab's efficacy. A graphical abstract and video abstract are available for this article.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Associations at baseline between PNIF and NC ( A ), LoS ( B ), and UPSIT ( C ) (combined SINUS-24 and SINUS-52 ITT). PNIF, NC, LoS, and UPSIT values are the average of the prior 7 days’ patient e-diary recordings. If fewer than four measurements were collected within 7 days before randomization, the baseline was the average of the four most recent measurements before randomization. ITT intention-to-treat, LoS loss of smell, NC nasal congestion/obstruction, PNIF peak nasal inspiratory flow, UPSIT University of Pennsylvania Smell Identification Test
非 KM Figure
Fig. 2Fig. 2 Associations between change in PNIF and NC from baseline to week 24 in patients treated with placebo ( A ) or dupilumab 300 mg q2w ( B ), and from baseline to week 52 in patients treated with placebo ( C ) or dupilumab 300 mg q2w ( D ). Calculated using PNIF and NC monthly average values. NC nasal congestion/obstruction, PNIF peak nasal inspiratory flow, q2w every 2 weeks
非 KM Figure
Fig. 3Fig. 3 Associations between change in PNIF and LoS from baseline to week 24 in patients treated with placebo ( A ) or dupilumab 300 mg q2w ( B ). Calculated using PNIF and LoS monthly average values. LoS loss of smell, PNIF peak nasal inspiratory flow, q2w every 2 weeks
非 KM Figure
Fig. 4Fig. 4 Associations between change in PNIF and UPSIT from baseline to week 24 in patients treated with placebo ( A ) or dupilumab 300 mg q2w ( B ). Calculated using PNIF and UPSIT monthly average values. PNIF peak nasal inspiratory flow, q2w every 2 weeks, UPSIT University of Pennsylvania Smell Identification Test
非 KM Figure